Stroke

Current Location

72 Stroke Trials Near You

Power is an online platform that helps thousands of Stroke patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
This trial tests whether taking blood-thinning medication continuously or only when a smart watch detects an irregular heartbeat is better for adults with a history of irregular heartbeats and moderate stroke risk.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:22 - 85

5350 Participants Needed

This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79

14012 Participants Needed

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 79

12301 Participants Needed

This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

728 Participants Needed

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2650 Participants Needed

MW189 for Brain Bleed

Cincinnati, Ohio
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cognitive/memory decline. Extant evidence supports our overarching hypothesis that LPC-DHA supplementation will be more effective than TAG-DHA for increasing central (CSF) DHA levels and improving biomarker profiles in elderly adults. To assess this hypothesis, the following aims are proposed: SPECIFIC AIM 1: To compare the effects of LPC-DHA and TAG-DHA supplementation on peripheral and CSF DHA levels in elderly adults experiencing early signs of cognitive/memory decline. SPECIFIC AIM 2: To compare the effects of LPC-DHA and TAG-DHA supplementation on neurotrophic and neurodegenerative biomarkers. Secondary Aim: To investigate whether changes in CSF DHA levels correlate with changes in objective measures of executive functioning and episodic memory performance.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:62 - 80

153 Participants Needed

People who had a stroke at least 6 months prior and who still have difficulty with walking will each be randomly assigned to receive either moderate or vigorous intensity walking exercise. Both protocols will be performed individually with a physical therapist for 45 minutes, 3x/week for 12 weeks. Measures including walking function will be assessed at baseline (PRE), after 4, 8 and 12 weeks of training (12WK) and at 3-month follow up (3moPOST), by raters who are unaware of the participant randomization.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30 - 85

156 Participants Needed

Caring for a family member after a stroke can be very difficult and worsen the physical and mental health of untrained caregivers. The TASK III intervention is a unique, comprehensive caregiver intervention program that enables caregivers to develop the necessary skills to manage care for the survivor, while also taking care of their own health.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

296 Participants Needed

Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The "Door-In-Door-Out" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US "stand up" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

900 Participants Needed

Swallowing impairments (dysphagia) frequently occur after stroke and have devastating consequences on overall health and quality of life, and long-term deficits in swallow function also increase risk of morbidity (e.g. depression) and mortality (i.e. aspiration pneumonia). As such, rehabilitation of swallow function to improve safety and efficiency of swallowing is essential in this population. This study aims to: 1) Provide preliminary data to evaluate the effect of a novel lingual endurance exercise on swallow function in individuals with post-stroke dysphagia; and 2) Collect preliminary data regarding changes in white matter tract diffusion and cortical thickness and from MRI data to better understand effects of lingual exercise training on neuroplasticity.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

70 Participants Needed

LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

4000 Participants Needed

This study will 1) Evaluate the prevalence of elevated (conditional or abnormal) transcranial Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia (SCA) living in Tanzania; 2) Obtain longitudinal data on TCD velocities in this population; and 3) Measure the effects of hydroxyurea therapy on TCD velocities and associated primary stroke risk.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:2 - 16

202 Participants Needed

Retatrutide for Obesity

Richmond, Indiana
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+

10000 Participants Needed

Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for stroke prevention in AF is consistently under-prescribed. In a pair of observational cohort analyses within the Mass General Brigham (MGB) health system, prescription of anticoagulation for stroke prevention in AF was less frequent in ambulatory clinic patients than in those who were hospitalized at the time of assessment (46.9% vs. 57.2%). Two single academic medical center randomized controlled trials demonstrated success for increasing adherence to guideline recommendations for stroke prevention in AF. To address the feasibility and impact of a computerized decision support (CDS) strategy in the non-tertiary care, community medical center setting, this study will involve a multicenter, cluster-randomized controlled trial of a more sophisticated CDS focused not only on implementation stroke prevention but also on bleeding risk assessment and management.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

2500 Participants Needed

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

44 Participants Needed

After a stroke, it is very common to lose the ability to open the affected hand. Occupational and physical rehabilitation therapy (OT and PT) combined with non-invasive brain stimulation may help a person recover hand movement. The purpose of this study is to compare 3 non-invasive brain stimulation protocols combined with therapy to see if they result in different amounts of recovery of hand movement after a stroke.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 90

63 Participants Needed

The purpose of this study is to examine the reflex excitability of the rectus femoris in individuals with and without post-stroke Stiff-Knee gait. We use electrical stimulation of the peripheral nerve innervating the rectus femoris for a well-controlled reflex stimulus. We are investigating whether reflex excitability of the rectus femoris correlates with gait kinematics.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

60 Participants Needed

The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

140 Participants Needed

The objectives of the study are to examine the performance and safety characteristics of the Millipede System when used for revascularization of patients with acute ischemic stroke due to Large Vessel Occlusions (LVOs) and to record associated clinical outcomes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

246 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38
This pilot study for stroke patients with chronic upper limb hemiplegia will examine the effects of non-invasive brain stimulation and neuromuscular electrical stimulation on hand motor control and corticospinal excitability. Specifically, this study will investigate the effects of timing and delivery of tDCS in conjunction with contralaterally controlled functional electrical stimulation.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+

15 Participants Needed

This trial is testing a small implanted device that helps stroke survivors walk better by sending electrical signals to their muscles. The device is surgically placed and helps the muscles contract, making it easier to walk. This method has been shown to improve walking ability in stroke patients.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 75

6 Participants Needed

This trial tests the safety of PP-007, a modified cow protein given through an IV, in stroke patients. It aims to improve blood flow and reduce brain damage. The study includes patients already receiving standard stroke treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting

24 Participants Needed

The goal of this clinical trial is to learn if operant conditioning can reduce spasticity in order to improve walking in stroke patient. The main questions it aims to answer are: * Can participants self-regulate reflex excitability * Can participants self-regulate reflex, reduce spasticity and improve walking Participants will undergo surface stimulation to evoke spinal reflexes and will be asked to control these reflexes therefore reducing spasticity. Researchers will compare result to able bodied participants to see if \[insert effects\]
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting

60 Participants Needed

This trial is testing a new device that removes blood clots from brain vessels in stroke patients with severe symptoms. The goal is to see if it works better than current methods.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

168 Participants Needed

The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

80 Participants Needed

The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients with large vessel occlusions (LVO) in the anterior circulation of Internal Carotid Artery (ICA), Middle Cerebral Arteries (M1 and M2) who achieve a reperfusion grade of Modified Treatment in Cerebral Ischemia Scale (mTICI) 2b or higher post-mechanical thrombectomy using Food and Drug Administration (FDA) approved devices.
Stay on current meds
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

132 Participants Needed

After a stroke, it is very common to lose the ability to open the affected hand. The purpose of this study is to compare the effects of three different therapies on recovery of hand function after stroke and determine if any one is better than the other.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:21 - 90

132 Participants Needed

The purpose of this study is to evaluate a surgically implanted functional electrical stimulation (FES) system to facilitate exercise, standing, stepping and/or balance in people with various degrees of paralysis.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 75

10 Participants Needed

Traditional rehabilitation approaches are time and personnel intensive and costly, and leave \~75% of stroke survivors with residual disability. We propose a clinical trial to determine effects of forced aerobic exercise (FE; i.e., mechanically supplemented) in facilitating upper and lower extremity motor recovery post-stroke in an outpatient rehabilitation setting, to elucidate neural and biochemical substrates of FE-induced motor recovery, and to evaluate cost effectiveness of a FE-centered intervention compared to traditional stroke rehabilitation. The global effect of FE has the potential to enhance recovery in a growing population of stroke survivors in a cost-effective manner, thus accelerating its clinical acceptance.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

66 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Stroke clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Stroke clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Stroke trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Stroke is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Stroke medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Stroke clinical trials?

Most recently, we added Computerized Decision Support for Stroke Prevention in Atrial Fibrillation, Angioplasty for Stroke Risk Reduction and CEREGLIDE 92 Catheter for Ischemic Stroke to the Power online platform.

Is it possible to 100% recover from a stroke?

A completely symptom-free recovery does happen, but it’s uncommon—about 1 in 10 stroke survivors have no noticeable deficits by 3–6 months, while many more regain independence yet live with minor limitations. Your odds rise if the stroke is small, treated within hours (clot-busting drugs or thrombectomy), and followed by early, high-intensity rehab; age, other illnesses, and strong family support also matter. Even when full recovery isn’t reached, the brain can keep rewiring for months or years, so aggressive therapy and strict control of blood pressure, cholesterol, and lifestyle risks remain worthwhile.

What triggers a stroke?

A stroke is triggered the instant blood can’t reach part of the brain—either because a clot suddenly blocks an artery or a weakened vessel bursts. Long-standing problems such as high blood pressure, atrial fibrillation, diabetes, smoking, and cholesterol build-up make the vessels fragile, while short-term sparks like a surge in blood pressure (heavy exertion, intense stress, cocaine or binge drinking), a bad infection, severe dehydration, or head/neck injury can tip things over the edge. Controlling the chronic risks and avoiding those sudden spikes are the surest ways to lower your odds.

What is the new procedure for stroke victims?

Two main “new” procedures are worth knowing about. If a stroke is caught within the first day, doctors can now thread a tiny device into the brain’s artery (mechanical thrombectomy) to pull out large clots—even up to 24 hours after symptoms start. For people who are six months or more past an ischemic stroke and still have arm weakness, a recently approved treatment called paired vagus-nerve stimulation implants a pacemaker-like device in the chest; brief pulses are delivered during therapy sessions and, in a large study, nearly doubled the number of patients who regained meaningful arm use compared with therapy alone. Ask your stroke or rehab specialist which option, if any, fits your stage of recovery and medical history.

What is the average age at the time of ischemic stroke?

Across contemporary U.S. and European studies, the average (mean) age at first ischemic stroke is about 70–72 years overall—roughly 71 years in men and 74–75 years in women. Most strokes still occur after 65, but nearly 15–20 % now happen before age 55, so personal risk depends more on controllable factors such as blood-pressure, diabetes, smoking, and atrial fibrillation than on age alone.

What are good signs after a brain stroke?

Good signs after a stroke are the things doctors see when the brain is healing: 1) steadily improving neurological function—e.g., a weak arm or leg starts to move, speech becomes clearer, swallowing is safe, thinking is sharper; 2) growing independence—being able to sit, stand, walk, dress, or bathe with less help each week; and 3) no new problems—vital signs remain stable, follow-up scans show no bleeding or new damage, and there are no new bouts of confusion or weakness. If progress keeps inching forward over the first days to months, that generally predicts a better long-term recovery, while sudden setbacks should prompt a call to the medical team.

Which side of the brain is worse to have a stroke?

Neither hemisphere is automatically “worse.” What harms you most is how big the stroke is, which critical areas it hits (for example, language centers on the left or spatial-awareness areas on the right), and how fast doctors can restore blood flow. Large right-side strokes carry a slightly higher risk of early swelling and heart-rhythm problems, while left-side strokes more often steal speech, but in the long run size, exact location, and treatment speed—not simple left vs. right—determine survival and disability.

How to stop a stroke in progress?

A stroke in progress can only be halted by hospital teams, so the single lifesaving move is to get the patient to a stroke-ready ER fast. Spot symptoms with the BE-FAST check (Balance, Eyes, Face, Arm, Speech, Time), call 911, note when symptoms started, keep the person upright and nil-by-mouth, and let EMS transport. Every minute saved lets doctors give clot-busting medicine (within ~4½ h) or remove a clot mechanically (up to 24 h in select cases), drastically reducing brain damage and disability.

What is the critical time after a stroke?

“Time is brain.” Call 911 the moment you notice stroke signs, because the sooner doctors see you, the more treatment choices you have: clot-busting medication helps most if started within 4½ hours, and a catheter procedure to pull out a large clot can work in carefully selected cases up to 24 hours—but outcomes get worse with every minute’s delay. Getting to the hospital fast also lets the team quickly scan your brain, control bleeding or swelling, and begin early rehab, all of which greatly improve the chance of recovery.

What heals the brain after a stroke?

First, rapid hospital treatment (clot-busting drugs or a catheter procedure, plus careful control of blood pressure, sugar and swelling) “saves” threatened brain tissue—so minutes matter. In the weeks and months that follow, the surviving brain rewires itself and grows new blood vessels, and that self-repair works best when you give it the right signals: daily, task-specific rehab exercises, regular aerobic activity, good sleep, and strict control of smoking, blood pressure, cholesterol and diabetes; tools like non-invasive brain stimulation or certain medications are optional add-ons guided by specialists. Put simply, the brain heals through a mix of early damage-limiting care and long-term, repetitive practice in a healthy body, with emerging technologies offering extra (but still experimental) help for some people.

What is the average stay in rehab after a stroke?

For patients able to tolerate intensive therapy, the average stay in a U.S. inpatient rehabilitation hospital is about 15–18 days (roughly 2–3 weeks); if a skilled-nursing rehab unit is needed, expect closer to 4–5 weeks before stepping down to outpatient or home therapy several times a week. How long you personally stay hinges on stroke severity, other medical problems, progress on daily-living skills, insurance rules, and the safety of your home setup—so ask the rehab team what specific goals you must meet to move to the next level of care.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security